BioDlink
BioDlink is an integrated biologics and ADC-focused CDMO providing one-stop development, GMP manufacturing, and commercial supply services from cell line to drug product. It serves global biopharmaceutical clients with proprietary conjugation, cell line, and digital lyophilization platforms, operating as a controlled subsidiary of WuXi XDC.
- Company typePublic
- Founded2010
- HeadquartersSuzhou, China
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What BioDlink does
BioDlink is an integrated biologics and antibody-drug conjugate (ADC) contract development and manufacturing organization (CDMO) headquartered in Suzhou Industrial Park, China. Founded in 2010 and listed on the Hong Kong Stock Exchange (ticker 1875.HK) since November 2019, the company operates a one-stop CDMO platform spanning cell line development, antibody manufacturing, conjugation process development, drug product formulation, lyophilization, and commercial GMP manufacturing. Its proprietary technology stack includes the GL-DisacLink® glycan-specific ADC conjugation platform (co-developed with Tangling Bio), the BDKcell® CHO-K1 cell line platform with reported 8-10 g/L antibody titers, the BDKLyo™ digital lyophilization modeling platform, and an OS one-step conjugation technology. BioDlink maintains 20,000+ L of monoclonal antibody manufacturing capacity, 960 kg of ADC drug substance capacity, and 4 commercial-scale production lines, with quality systems certified to FDA, EMA, NMPA, PMDA, ANVISA, and EU QP standards.
The company's revenue model combines project-based CDMO service fees (fixed-fee and milestone-based contracts tied to project progression and regulatory achievements) with revenue from proprietary commercial products including the bevacizumab biosimilar Pusintin and MEIYOUHENG (Becotatug Vedotin), the world's first EGFR-targeted ADC developed with Lepu Biopharma. As of 2025, BioDlink had served 108 cumulative clients across 213 projects, with ADC-related projects comprising 68% of the pipeline and overseas clients representing 19% of the client base. The company pursues a sales-led go-to-market model with dedicated business development teams engaging global biopharmaceutical clients at major industry events and through direct enterprise outreach, supported by technical publications and conference presence.
Following a strategic 2020 pivot from biosimilars to ADC-focused CDMO services under CEO Dr. Liu Jun, BioDlink materially expanded its ADC platform, secured multiple international GMP certifications, and signed a RMB 3.08 billion order backlog (up 61% YoY). In late 2025, WuXi XDC (HKG: 2268) completed a $400 million voluntary offer for BioDlink, making it a controlled subsidiary and integrating it into WuXi XDC's broader ADC/XDC CRDMO platform as of June 2026.
BioDlink firmographics
Firmographics- Name
- BioDlink
- Legal name
- BioDlink International Company Limited
- Website
- https://biodlink.com
- Company type
- Public
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- BioDlink is an integrated biologics and ADC-focused CDMO providing one-stop development, GMP manufacturing, and commercial supply services from cell line to drug product. It serves global biopharmaceutical clients with proprietary conjugation, cell line, and digital lyophilization platforms, operating as a controlled subsidiary of WuXi XDC.
- Ownership category
- akta.pro rank
BioDlink industry classification
Industry- Product category
- Biologics Contract Development and Manufacturing (CDMO)
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
Keywords
Where BioDlink is headquartered
LocationHeadquarters
- HQ city
- Suzhou
- HQ country
- China
- HQ region
- Asia
Offices4 records
Markets served
BioDlink business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- CDMO/CMO Services: Contract development and manufacturing organization services for biologics including ADC, monoclonal antibodies, and other biological drugs. Services span from early R&D, process development, analytical method development, GMP manufacturing, to regulatory filing support. Revenue is project-based with a mix of fixed-fee contracts for defined services and milestone-based payments tied to project progress and regulatory achievements.
- Product Sales: Sales of proprietary biological drugs including bevacizumab biosimilar (朴欣汀/Pusintin), which has been approved in multiple countries internationally. Also includes other marketed products.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Project-based CDMO service pricing tailored to client requirements |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
BioDlink product offering
Product offeringCore offering
BioDlink is a biologics Contract Development and Manufacturing Organization (CDMO) providing one-stop services spanning antibody R&D, cell line development, ADC conjugation process development, drug substance and drug product manufacturing, lyophilization, analytical method development, technology transfer, and regulatory affairs support. The company operates an integrated ADC/XDC CRDMO platform with over 20,000 L of monoclonal antibody manufacturing capacity and 960 kg of ADC drug substance capacity, serving global biopharmaceutical clients from early R&D through commercial manufacturing.
Product overview
BioDlink is a biologics CDMO (Contract Development and Manufacturing Organization) providing one-stop CDMO solutions. The company operates a platform-plus-services model centered on its ADC Integrated Platform, which encompasses R&D services, conjugation process development, drug formulation and lyophilization, and analysis services. Supporting platforms include the Protein/Antibody Platform (cell culture and purification), GMP Manufacturing (20,000+ L capacity), Technology Transfer, Quality Management, and Regulatory Affairs services. The company also offers proprietary technology platforms including GL-DisacLink® for glycan site-specific ADC conjugation, BDKcell® CHO-K1 cell line development, and BDKLyo™ digital lyophilization optimization. Commercial products include MEIYOUHENG (Becotatug Vedotin), the world's first EGFR-targeted ADC, and 朴欣汀® (Pusintin), a bevacizumab biosimilar.
Differentiator
Problem solved
Functional benefit
Brands
- BDKcell CHO-K1: Proprietary cell line development platform with optimized CHO-K1 cell system, featuring short development cycle, high expression, and good stability
- BDKLyo™
- GL-DisacLink®
- 朴欣汀 (Pusintin)
- 美佑恒 (MEIYOUHENG)
Products and services
- ADC Integrated Platform R&D, process development, and commercial manufacturing platform for ADC including monoclonal antibody production, drug substance (DS), and drug product (DP). Covers conjugation process development, formulation, lyophilization, and analysis services for biopharmaceutical clients developing ADC drugs.
- Protein/Antibody Platform Cell culture process development, purification process development, lyophilization process, and analysis services for proteins and antibodies based on QbD concept. Designed for biopharmaceutical clients developing monoclonal antibodies, bispecific antibodies, and fusion proteins.
- GMP Manufacturing Large-scale commercial GMP production base for biological drugs with multiple complete upstream and downstream production lines. Total manufacturing capacity exceeds 20,000 L for monoclonal antibodies and 960 kg for ADC drug substance, including drug substance and drug product manufacturing.
- Technology Transfer Efficient technology transfer services based on mutual trust and reasonable control strategies, ensuring smooth project implementation between clients' R&D processes and BioDlink's manufacturing scale-up.
- Quality Management GMP-compliant quality management system conforming to commercial manufacturing standards, running through from R&D to commercialization, supporting multiple marketed products. Includes Quality Control and Quality Assurance functions compliant with FDA, EMA, and NMPA regulations.
- Regulatory Affairs
Quantifiable outcome
- Successfully enabled the world's first EGFR-targeted ADC drug (Becotatug Vedotin) commercial launch in China, marking first CDMO-manufactured ADC to receive approval.
- +4 more outcomes
Companies that use BioDlink
Customer profileNamed customers11 records
Segments1 record
Ideal customer profiles3 records
BioDlink technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature9 records
BioDlink partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered strategic and core.
- Akesobio (爱科百发)strategicCDMO partnership for AK0406 Antiviral Fc Conjugate (AFC) drug for influenza treatment. BioDlink provided full-chain development from cell line development, process development, analytical method establishment, formulation development to clinical sample production, completing the entire process within 12 months.
- Chengdu Kanghong Pharmaceutical (成都康弘药业)coreCDMO partnership for KH815 dual-payload ADC development. BioDlink completed process development, manufacturing, and regulatory submission activities for this world's first dual-payload ADC to enter clinical trials, finishing 1.5 months ahead of schedule.
- WuXi XDCcoreWuXi XDC made a voluntary offer to acquire BioDlink for approximately $400 million. WuXi XDC completed acquisition of BioDlink's Suzhou site and became a controlled subsidiary in 2026, with BioDlink continuing to operate as part of WuXi XDC's integrated ADC/XDC CRDMO platform.
- Lepu Biopharma (乐普生物)coreStrategic CDMO partnership for the development and manufacturing of Becotatug Vedotin (美佑恒), the world's first EGFR-targeted ADC drug. BioDlink provided end-to-end services from technology transfer, clinical sample production, PPQ batches, PAI inspection support, to BLA filing, culminating in NMPA approval in October 2025. The successful collaboration marked both the world's first EGFR ADC approval and the first ADC drug in China fully manufactured by a CDMO partner.
- Hutchmed (和黄医药)strategicCDMO service partnership for multiple projects including key ADC products. BioDlink was awarded 'Best Collaboration Partner' by Hutchmed for service excellence on both projects.
- Earendil LabsstrategicTechnology licensing partnership for WuXiTecan-2 with potential consideration up to US$885 million, as part of WuXi XDC's strategic technology expansion.
- Kexing BioPharm (科兴制药)strategicPartnership for international commercialization of bevacizumab biosimilar in emerging markets. Kexing leverages its overseas registration and channel advantages for rapid market access in Latin America and other regions, while BioDlink provides manufacturing. Bevacizumab approved in 5 countries including Nigeria, Pakistan, Colombia, Indonesia, and Bolivia.
- Yibu Bio (宜联生物)strategicPartnership where Yibu Bio partnered with BioNTech for HER3-targeted ADC development. BioDlink provides CDMO services including GMP formulation production for Yibu Bio's ADC pipeline.
- HaoYuan Pharmaceutical (皓元医药)strategicStrategic partnership to create a comprehensive ADC CDMO service platform. BioDlink provides mAb production and ADC CMC development while HaoYuan provides linker, payload, and Payload-Linker intermediates, enabling end-to-end services from R&D to industrialization.
- TangLing Bio (糖岭生物)strategicStrategic partnership for DisacLink™ glycan-specific ADC conjugation technology. Joint technology development, process optimization and commercialization scaling. BioDlink licensed to use DisacLink™ platform for CDMO services, providing industrial manufacturing capability for this advanced conjugation technology.
- BioRay Bio (博锐生物)strategicFull-spectrum CDMO strategic partnership for ADC development and commercialization. BioDlink provides one-stop, end-to-end CDMO platform services for multiple ADC R&D projects, supporting pipeline from development through IND and future commercial manufacturing.
- Jeminia (济民可信)strategicStrategic CDMO partnership for drug R&D and commercial manufacturing. Previously completed COVID-19 neutralizing antibody JMB2002 commercial scale-up 1.5 months ahead of schedule. The partnership was formalized into a broader strategic collaboration agreement.
- Bochu Bio (博瑞医药)strategicStrategic ADC CDMO partnership combining BioDlink's monoclonal antibody production and ADC CMC process development with Bochu's linker and payload intermediate capabilities. Both companies are located in Suzhou Industrial Park, enabling seamless supply chain integration and reducing cross-regional regulatory risks.
Scale indicators14 records
Recent moves9 records
Expansion highlights6 records
BioDlink competitors and assessment
Company assessmentBroad incumbents
- Lonza Biologics: Global leader in biologics manufacturing with extensive mammalian cell culture capacity. Offers comparable CDMO services (cell line, process development, GMP manufacturing) at much larger scale. Represents the gold standard incumbent that BioDlink competes against in international markets.
- WuXi Biologics: Global leader in biologics CDMO services and parent of WuXi XDC (which owns BioDlink). Offers end-to-end biologics development and manufacturing. Comparable to BioDlink on the biologics manufacturing side, though broader and more established in mAb CDMO services.
- Samsung Biologics: Major Asian-headquartered biologics CDMO with very large-scale mammalian manufacturing capacity. Comparable in terms of biologics manufacturing focus and Asian geographic positioning, though significantly larger and more established than BioDlink.
- Patheon (Thermo Fisher): Thermo Fisher's CDMO business offering biologics and small molecule manufacturing services globally. Comparable in terms of integrated CDMO service model across drug substance and drug product, though operates at vastly larger scale with broader service portfolio.
- Catalent (Novo Holdings): Global CDMO offering biologics, cell therapy, and drug product services including lyophilization. Recently acquired by Novo Holdings. Comparable to BioDlink's drug product formulation and lyophilization services, plus broader biologics CDMO offerings.
Direct peers
- Pharmaron: China-headquartered CRO/CDMO offering biologics and small molecule development and manufacturing services. Comparable to BioDlink's integrated service model and target customer base of biotech companies seeking CDMO partnerships in Asia.
- TOT Biopharma: Hong Kong-listed Chinese biologics CDMO offering antibody drug substance and drug product manufacturing, with PMDA foreign manufacturer accreditation. Direct peer to BioDlink in the Chinese biologics CDMO market with similar size and customer profile (some sources reference TOT BIOPHARM in connection with BioDlink's PMDA accreditation).
- AGC Biologics: Global biologics CDMO offering microbial and mammalian cell culture-based manufacturing, including cell therapy services. Direct peer in the biologics CDMO space with similar service offerings (cell line development, process development, GMP manufacturing) and comparable customer profile.
- WuXi XDC: Direct peer and now parent company. WuXi XDC is a Hong Kong-listed CRDMO focused on ADC and bioconjugates, offering antibody, conjugation, and drug product services. Most directly comparable to BioDlink given overlapping ADC CDMO capabilities and shared customer base, including the recent $400M acquisition of BioDlink.
- Genscript ProBio: China-based biologics CDMO offering cell line development, plasmid/mRNA, viral vector, and protein manufacturing services. Direct competitor to BioDlink in the Chinese biologics CDMO market with similar target customers (Chinese and international biotech companies developing biologics).
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
BioDlink social profiles
Digital presenceBioDlink compliance and trust
Trust signalCompliance11 records
BioDlink financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioDlink leadership team
Management profileNumber of profiles
Profiles9 records
BioDlink funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioDlink M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioDlink
What does BioDlink do?
BioDlink is a biologics Contract Development and Manufacturing Organization (CDMO) providing one-stop services spanning antibody R&D, cell line development, ADC conjugation process development, drug substance and drug product manufacturing, lyophilization, analytical method development, technology transfer, and regulatory affairs support. The company operates an integrated ADC/XDC CRDMO platform with over 20,000 L of monoclonal antibody manufacturing capacity and 960 kg of ADC drug substance capacity, serving global biopharmaceutical clients from early R&D through commercial manufacturing.
Is BioDlink a public or private company?
BioDlink is a public company. It is classified as public and is currently operating.
When was BioDlink founded?
BioDlink was founded in 2010. It employs 501 to 1,000 people.
Where is BioDlink based?
BioDlink is headquartered in Suzhou, China, in the Asia region.
How does BioDlink make money?
Two revenue lines are on record. CDMO/CMO Services are the primary driver. The others are product Sales.
Who are BioDlink's main competitors?
Broad incumbents on record are Lonza Biologics, WuXi Biologics, Samsung Biologics, Patheon (Thermo Fisher) and Catalent (Novo Holdings). Direct peers are Pharmaron, TOT Biopharma, AGC Biologics, WuXi XDC and Genscript ProBio.
Does BioDlink have an API?
No public API is recorded for BioDlink.
What industry is BioDlink in?
BioDlink's product category is Biologics Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 325414 and its SIC code is 2834.